Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.72
FRX's Cash to Debt is ranked higher than
59% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.08 vs. FRX: 0.72 )
FRX' s 10-Year Cash to Debt Range
Min: 0.72   Max: No Debt
Current: 0.72

Equity to Asset 0.51
FRX's Equity to Asset is ranked higher than
59% of the 728 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.60 vs. FRX: 0.51 )
FRX' s 10-Year Equity to Asset Range
Min: 0.51   Max: 0.92
Current: 0.51

0.51
0.92
F-Score: 6
Z-Score: 4.43
M-Score: -3.04
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 3.06
FRX's Operating margin (%) is ranked higher than
62% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.25 vs. FRX: 3.06 )
FRX' s 10-Year Operating margin (%) Range
Min: -23.98   Max: 37.5
Current: 3.06

-23.98
37.5
Net-margin (%) 4.53
FRX's Net-margin (%) is ranked higher than
67% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. FRX: 4.53 )
FRX' s 10-Year Net-margin (%) Range
Min: -8.41   Max: 27.7
Current: 4.53

-8.41
27.7
ROE (%) 2.68
FRX's ROE (%) is ranked higher than
62% of the 752 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.97 vs. FRX: 2.68 )
FRX' s 10-Year ROE (%) Range
Min: -3.77   Max: 26.78
Current: 2.68

-3.77
26.78
ROA (%) 1.38
FRX's ROA (%) is ranked higher than
63% of the 777 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.87 vs. FRX: 1.38 )
FRX' s 10-Year ROA (%) Range
Min: -3.37   Max: 22.71
Current: 1.38

-3.37
22.71
ROC (Joel Greenblatt) (%) 13.43
FRX's ROC (Joel Greenblatt) (%) is ranked higher than
73% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.60 vs. FRX: 13.43 )
FRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -32.58   Max: 199.83
Current: 13.43

-32.58
199.83
Revenue Growth (%) -4.20
FRX's Revenue Growth (%) is ranked higher than
56% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. FRX: -4.20 )
FRX' s 10-Year Revenue Growth (%) Range
Min: -5.6   Max: 44.6
Current: -4.2

-5.6
44.6
EBITDA Growth (%) -31.60
FRX's EBITDA Growth (%) is ranked higher than
51% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. FRX: -31.60 )
FRX' s 10-Year EBITDA Growth (%) Range
Min: -57.6   Max: 71
Current: -31.6

-57.6
71
EPS Growth (%) -44.60
FRX's EPS Growth (%) is ranked higher than
51% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. FRX: -44.60 )
FRX' s 10-Year EPS Growth (%) Range
Min: -44.6   Max: 75
Current: -44.6

-44.6
75
» FRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

FRX Guru Trades in Q3 2013

Jean-Marie Eveillard 648,160 sh (New)
Dodge & Cox 3,441,441 sh (New)
Murray Stahl 7,616 sh (New)
Steven Cohen 46,257 sh (+166.09%)
Diamond Hill Capital 841,118 sh (+15.18%)
Vanguard Health Care Fund 26,666,866 sh (unchged)
Bernard Horn 62,200 sh (unchged)
Carl Icahn 30,662,005 sh (unchged)
Bill Nygren 4,950,000 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons 127,200 sh (-58.25%)
Jeremy Grantham 18,518 sh (-85.7%)
Richard Pzena 13,075 sh (-98.59%)
» More
Q4 2013

FRX Guru Trades in Q4 2013

Paul Tudor Jones 16,758 sh (New)
Ray Dalio 201,461 sh (New)
Dodge & Cox 7,647,837 sh (+122.23%)
Jean-Marie Eveillard 964,630 sh (+48.83%)
Murray Stahl 9,185 sh (+20.6%)
Bernard Horn 62,200 sh (unchged)
Carl Icahn 30,662,005 sh (unchged)
Bill Nygren 4,950,000 sh (unchged)
Vanguard Health Care Fund 26,666,866 sh (unchged)
Richard Pzena Sold Out
Jim Simons Sold Out
Jeremy Grantham 13,948 sh (-24.68%)
Diamond Hill Capital 413,694 sh (-50.82%)
Steven Cohen 8,344 sh (-81.96%)
» More
Q1 2014

FRX Guru Trades in Q1 2014

Jim Simons 704,874 sh (New)
Joel Greenblatt 11,598 sh (New)
Mario Gabelli 247,700 sh (New)
Jeremy Grantham 252,000 sh (+1706.71%)
Steven Cohen 22,457 sh (+169.14%)
Bernard Horn 62,200 sh (unchged)
Carl Icahn 30,662,005 sh (unchged)
Ray Dalio Sold Out
Diamond Hill Capital Sold Out
Murray Stahl 8,432 sh (-8.2%)
Jean-Marie Eveillard 806,230 sh (-16.42%)
Vanguard Health Care Fund 20,583,766 sh (-22.81%)
Dodge & Cox 3,888,618 sh (-49.15%)
Bill Nygren 1,950,000 sh (-60.61%)
Paul Tudor Jones 2,200 sh (-86.87%)
» More
Q2 2014

FRX Guru Trades in Q2 2014

Louis Moore Bacon 15,810 sh (New)
Jim Simons 834,300 sh (+18.36%)
Jean-Marie Eveillard 806,230 sh (unchged)
Bernard Horn 62,200 sh (unchged)
Joel Greenblatt Sold Out
Carl Icahn Sold Out
Paul Tudor Jones Sold Out
Murray Stahl Sold Out
Bill Nygren Sold Out
Vanguard Health Care Fund 15,716,666 sh (-23.65%)
Mario Gabelli 183,200 sh (-26.04%)
Jeremy Grantham 170,000 sh (-32.54%)
Dodge & Cox 45,100 sh (-98.84%)
» More
» Details

Insider Trades

Latest Guru Trades with FRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Carl Icahn 2014-06-30 Sold Out 8.6%$86.76 - $100.04 $ 996%0
Vanguard Health Care Fund 2014-06-30 Reduce -23.65%1.25%$86.76 - $100.04 $ 996%15716666
Dodge & Cox 2014-06-30 Reduce -98.84%0.37%$86.76 - $100.04 $ 996%45100
Mario Gabelli 2014-06-30 Reduce -26.04%0.03%$86.76 - $100.04 $ 996%183200
Joel Greenblatt 2014-06-30 Sold Out 0.02%$86.76 - $100.04 $ 996%0
Vanguard Health Care Fund 2014-03-31 Reduce -22.81%1.12%$58.47 - $99.72 $ 9925%20583766
Dodge & Cox 2014-03-31 Reduce -49.15%0.24%$58.47 - $99.72 $ 9924%3888618
Mario Gabelli 2014-03-31 New Buy0.12%$58.47 - $99.72 $ 9924%247700
Ray Dalio 2014-03-31 Sold Out 0.1%$58.47 - $99.72 $ 9924%0
Joel Greenblatt 2014-03-31 New Buy0.02%$58.47 - $99.72 $ 9924%11598
Dodge & Cox 2013-12-31 Add 122.23%0.26%$42.65 - $60.19 $ 9997%7647837
Ray Dalio 2013-12-31 New Buy0.1%$42.65 - $60.19 $ 9997%201461
Jean-Marie Eveillard 2013-12-31 Add 48.83%0.05%$42.65 - $60.19 $ 9997%964630
Dodge & Cox 2013-09-30 New Buy0.17%$41.71 - $44.78 $ 99128%3441441
Jean-Marie Eveillard 2013-09-30 New Buy0.08%$41.71 - $44.78 $ 99128%648160
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Forest Laboratories Inc

Bernard Horn Comments on Forest Laboratories - Aug 26, 2014

Pharmaceutical maker Forest Laboratories (FRX) had double digit returns on news of its acquisition by Actavis PLC, the world’s second largest generic drug maker. Prior to this transaction, Forest Labs conducted a company restructuring, increased its product pipeline and initiated a stock buyback, all of which helped boost the stock valuation at the time of Actavis’ $25 billion acquisition bid.

From Bernard Horn (Trades, Portfolio)’s Polaris Global Value Fund 2Q 2014 Message to Our Shareholders.

Check out Bernard Horn latest stock trades

Bernard Horn Comments on Forest Laboratories - Aug 07, 2014

Forest Laboratories (FRX) continued to benefit from the news of its acquisition by Actavis PLC, the world’s second largest generic drug maker.



From Bernard Horn (Trades, Portfolio)’s Polaris Global Value Fund Second Quarter 2014 Shareholder Letter.



Check out Bernard Horn latest stock trades

Diamond Hill Capital Comments on Forest Laboratories Inc - Jun 26, 2014

We closed our position in drug manufacturer Forest Laboratories, Inc. (FRX) as the market reacted positively to the news that Actavis, Inc. PLC would buy Forest Laboratories at a significant premium, and the share price approached our estimate of intrinsic value.



From Diamond Hill Capital's Select Fund Commentary – First Quarter 2014.



Check out Diamond Hill Capital latest stock trades

Bill Nygren Comments on Forest Laboratories - Apr 14, 2014

After returning 40% last quarter, Forest (FRX) returned another 52% in the first quarter as the company agreed to be acquired by Actavis for both cash and stock. We believe the acquisition price was full and fair. While our investment thesis – that Forest’s new drug launches would be successful and leverage the company’s expenses – did not have the chance to transpire, we are more than pleased that the stock price reached our estimated value in short order. It’s not uncommon for the management of companies in transition to resist being acquired before their strategies to create value are fully realized. We applaud the leaders at Forest for their willingness to pull forward this value, even if it denied them the personal satisfaction of seeing their efforts realized in the coming years. We believe this could serve as a lesson for the leadership of other public companies. If someone wants to pay a fair price on a risk-adjusted basis for ‘what could be’ in your business, you owe it to your shareholders to realize this value so that they can recycle their capital into other attractively valued investments.

From Bill Nygren (Trades, Portfolio)'s Oakmark Select Fund first quarter 2014 investor letter.

Check out Bill Nygren latest stock trades

Bill Nygren Comments on Forest Laboratories - Apr 10, 2014

The best performing stock in the quarter was Forest Laboratories (Forest), up 54%. Forest has been an incredibly successful investment for the Oakmark Fund, and we offer our congratulations to the company’s board and management team for maximizing per-share value for shareholders. It has only been one year since we first wrote about our purchase of Forest, and since then, the share price has increased 149%. Please refer to the Oakmark Select commentary for a more detailed description of our tax-efficient sale strategy for Forest.

From Bill Nygren (Trades, Portfolio)'s Oakmark Fund first quarter 2014 commentary.

Check out Bill Nygren latest stock trades

Diamond Hill Capital Comments on Forest Laboratories Inc. - Mar 07, 2014

Drug manufacturer Forest Laboratories, Inc. (FRX) announced results for the most recent quarter that surpassed expectations. More importantly, the company's new CEO announced aggressive cost cutting targets and a $1 billion share buyback plan.

From Diamond Hill Capital (Trades, Portfolio)'s Select Fund Commentary for fourth quarter 2013.

Check out Diamond Hill Capital latest stock trades

Bill Nygren Comments on Forest Labs - Jan 09, 2014

As value investors with a long-term horizon, we are happy to patiently wait for undervalued securities to appreciate toward our estimates of intrinsic value.  Occasionally, we are pleased to see the value gap close more rapidly, which is what has happened with Forest Labs over the past three quarters.  Forest Labs appointed a new CEO, who quickly introduced a substantial cost-cutting program and a more shareholder-friendly capital allocation strategy.  These measures helped Forest Labs enjoy a 60% increase in stock price since January 2013.

 

From Bill Nygren (Trades, Portfolio)'s fourth quarter 2013 commentary.

Check out Bill Nygren latest stock trades

Bill Nygren Comments on Forest Laboratories - Oct 08, 2013

In the past fiscal year, we purchased Forest Laboratories, Kennametal, and Oracle, which were all discussed in prior letters. Forest (FRX)’s many new drug launches remain on track with our original estimates and we look forward to this value being demonstrated in the income statement as sales ramp relative to expenses over the next several years.

From Bill Nygren's Oakmark Select Fund third quarter 2013 commentary.
Check out Bill Nygren latest stock trades

Bill Nygren Comments on Forest Laboratories - Apr 23, 2013

During the quarter we added Forest Laboratories (FRX)(FRX - $37) to the portfolio. Forest doesn't have the high yield or low P/E that has attracted investors to other pharmaceutical stocks, but it does have a collection of newly introduced drugs that we believe is worth significantly more than the stock price. A more complete explanation of our interest in Forest is available in the Oakmark Fund quarterly letter.

The purchase of Forest was largely funded by a continued reduction in our Discovery position. We couldn't be more pleased with Discovery’s growth in profitability, largely due to an increased number of viewers across its networks. We are also pleased with its use of cash to repurchase shares. But with the stock trading at $70, compared to less than $9 five years ago, it is hard to argue that investors are not giving them appropriate credit for that performance.

From Bill Nygren's Oakmark Select Fund first quarter 2013 commentary.


Check out Bill Nygren latest stock trades

Top Ranked Articles about Forest Laboratories Inc

Bernard Horn Comments on Forest Laboratories
Pharmaceutical maker Forest Laboratories (FRX) had double digit returns on news of its acquisition by Actavis PLC, the world’s second largest generic drug maker. Prior to this transaction, Forest Labs conducted a company restructuring, increased its product pipeline and initiated a stock buyback, all of which helped boost the stock valuation at the time of Actavis’ $25 billion acquisition bid. Read more...
Bernard Horn’s Polaris Global Value Fund 2Q 2014 Message to Our Shareholders
Dear Fellow Shareholder, Read more...
Bernard Horn Comments on Forest Laboratories
Forest Laboratories (FRX) continued to benefit from the news of its acquisition by Actavis PLC, the world’s second largest generic drug maker. Read more...
Diamond Hill Capital Comments on Forest Laboratories Inc
We closed our position in drug manufacturer Forest Laboratories, Inc. (FRX) as the market reacted positively to the news that Actavis, Inc. PLC would buy Forest Laboratories at a significant premium, and the share price approached our estimate of intrinsic value. Read more...
GuruFocus Guru of the 2013 Carl Icahn's Top First Quarter Holdings
GuruFocus’ Guru of the Year for 2013 reported his first quarter portfolio holdings today which highlighted 19 stocks valued at over $32.3 billion. This is a notable jump up from the company’s fourth quarter stocks which were valued at $30.4 billion. Over the past quarter the guru bought into one new company, eBay (EBAY) and only made one reduction in Netflix (NFLX). Read more...
International Guru Bernard Horn Reports His Top Five in the First Quarter
Guru Bernard Horn (Trades, Portfolio) of the Polaris Global Value Fund reported his first quarter holdings earlier today. The guru focuses his investments on two philosophies – that the country and industry factors are important determinants of security prices, and that global market fluctuations produce mispriced stocks. Read more...
Mario Gabelli’s GAMCO Investors Top 5 New Stocks
Mario Gabelli (Trades, Portfolio), whose Gabelli Asset Management Company (GAMCO) has $43 billion in managed assets, has returned 27% on average over the past five years in his largest strategy, the Gabelli Asset Fund (GABAX). Gabelli and his managers expressed their investing philosophy and tack of adhering to it regardless of upcoming market conditions in the Gabelli Asset Fund first quarter letter: Read more...
Bill Nygren Comments on Forest Laboratories
After returning 40% last quarter, Forest (FRX) returned another 52% in the first quarter as the company agreed to be acquired by Actavis for both cash and stock. We believe the acquisition price was full and fair. While our investment thesis – that Forest’s new drug launches would be successful and leverage the company’s expenses – did not have the chance to transpire, we are more than pleased that the stock price reached our estimated value in short order. It’s not uncommon for the management of companies in transition to resist being acquired before their strategies to create value are fully realized. We applaud the leaders at Forest for their willingness to pull forward this value, even if it denied them the personal satisfaction of seeing their efforts realized in the coming years. We believe this could serve as a lesson for the leadership of other public companies. If someone wants to pay a fair price on a risk-adjusted basis for ‘what could be’ in your business, you owe it to your shareholders to realize this value so that they can recycle their capital into other attractively valued investments. Read more...
Bill Nygren Comments on Forest Laboratories
The best performing stock in the quarter was Forest Laboratories (Forest), up 54%. Forest has been an incredibly successful investment for the Oakmark Fund, and we offer our congratulations to the company’s board and management team for maximizing per-share value for shareholders. It has only been one year since we first wrote about our purchase of Forest, and since then, the share price has increased 149%. Please refer to the Oakmark Select commentary for a more detailed description of our tax-efficient sale strategy for Forest. Read more...
Diamond Hill Capital Comments on Forest Laboratories Inc.
Drug manufacturer Forest Laboratories, Inc. (FRX) announced results for the most recent quarter that surpassed expectations. More importantly, the company's new CEO announced aggressive cost cutting targets and a $1 billion share buyback plan. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 161.20
FRX's P/E(ttm) is ranked higher than
58% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.30 vs. FRX: 161.20 )
FRX' s 10-Year P/E(ttm) Range
Min: 6.55   Max: 165.09
Current: 161.2

6.55
165.09
P/B 4.35
FRX's P/B is ranked higher than
56% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. FRX: 4.35 )
FRX' s 10-Year P/B Range
Min: 1.4   Max: 9.1
Current: 4.35

1.4
9.1
P/S 7.39
FRX's P/S is ranked lower than
54% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. FRX: 7.39 )
FRX' s 10-Year P/S Range
Min: 1.49   Max: 11.03
Current: 7.39

1.49
11.03
PFCF 341.38
FRX's PFCF is ranked higher than
71% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. FRX: 341.38 )
FRX' s 10-Year PFCF Range
Min: 5.83   Max: 574
Current: 341.38

5.83
574
EV-to-EBIT 224.98
FRX's EV-to-EBIT is ranked higher than
61% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.72 vs. FRX: 224.98 )
FRX' s 10-Year EV-to-EBIT Range
Min: 3.3   Max: 232.1
Current: 224.98

3.3
232.1
Shiller P/E 44.54
FRX's Shiller P/E is ranked higher than
73% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 150.63 vs. FRX: 44.54 )
FRX' s 10-Year Shiller P/E Range
Min: 8.21   Max: 83.93
Current: 44.54

8.21
83.93

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 2.55
FRX's Price/DCF (Projected) is ranked higher than
83% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.06 vs. FRX: 2.55 )
FRX' s 10-Year Price/DCF (Projected) Range
Min: 0.53   Max: 4.91
Current: 2.55

0.53
4.91
Price/Median PS Value 2.23
FRX's Price/Median PS Value is ranked higher than
55% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.26 vs. FRX: 2.23 )
FRX' s 10-Year Price/Median PS Value Range
Min: 0.52   Max: 3.07
Current: 2.23

0.52
3.07
Earnings Yield (Greenblatt) 0.40
FRX's Earnings Yield (Greenblatt) is ranked lower than
60% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. FRX: 0.40 )
FRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 30.1
Current: 0.4

0.4
30.1
Forward Rate of Return (Yacktman) -31.10
FRX's Forward Rate of Return (Yacktman) is ranked lower than
52% of the 633 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.43 vs. FRX: -31.10 )
FRX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -30.8   Max: 68.6
Current: -31.1

-30.8
68.6

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, MRX, ESALF » details
Traded in other countries:FQX.Germany
Forest Laboratories, Inc. is a Delaware corporation organized in 1956. The Company develops, manufactures and sells branded forms of ethical drug products most of which require a physician's prescription. The Company's most important United States products are marketed directly, or 'detailed,' to physicians by its salesforces. It emphasizes detailing to physicians of those branded ethical drugs which have the most potential for growth and benefit to patients. The Company also develops and introduces new products, including products developed in collaboration with licensing partners. The Company's products include those developed by it and those acquired from other pharmaceutical companies and integrated into its marketing and distribution systems. It actively promotes in the United States those branded products which have the most potential for growth and patient benefit, and which enable its salesforces to concentrate on groups of physicians who are high prescribers of its products. Such products include: Lexapro, its SSRI for the treatment of major depression in adults and adolescents and GAD in adults; Namenda, its NMDA antagonist for the treatment of moderate and severe Alzheimer's disease; Bystolic, its beta-blocker for the treatment of hypertension; and Savella, its newest product, an SNRI for the management of fibromyalgia. The Company's United Kingdom and Ireland subsidiaries sell both ethical products and over-the-counter preparations. Their most important products include Sudocrem, a topical preparation for the treatment of diaper rash; Colomycin, an antibiotic used in the treatment of cystic fibrosis; Infacol, used to treat infant colic; and Exorex, used in the treatment of eczema and psoriasis. The pharmaceutical industry is subject to comprehensive government regulation which substantially increases the difficulty and cost incurred in obtaining the approval to market newly proposed drug products and maintaining the approval to market existing drugs.
» More Articles for FRX

Headlines

Articles On GuruFocus.com
Bernard Horn Comments on Forest Laboratories Aug 26 2014 
Bernard Horn’s Polaris Global Value Fund 2Q 2014 Message to Our Shareholders Aug 26 2014 
Global Guru Bernard Horn Reports his Top Five from the Second Quarter Aug 22 2014 
Guru of the Year – Carl Icahn’s Top Five Holdings Aug 17 2014 
Bernard Horn Comments on Forest Laboratories Aug 07 2014 
Diamond Hill Capital Comments on Forest Laboratories Inc Jun 26 2014 
GuruFocus Guru of the 2013 Carl Icahn's Top First Quarter Holdings May 15 2014 
International Guru Bernard Horn Reports His Top Five in the First Quarter May 07 2014 
Mario Gabelli’s GAMCO Investors Top 5 New Stocks May 07 2014 
Dodge & Cox First Quarter 2014 Commentary May 06 2014 

More From Other Websites
Drugmakers Shire, AbbVie near $53B merger Jul 14 2014
FOREST LABORATORIES, LLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion... Jul 03 2014
Forest Laboratories, Inc. -- Moody's upgrades bonds of Forest Labs to Baa3 Jul 01 2014
Actavis and Forest Receive U.S. FTC Clearance for Actavis’ Proposed Acquisition of Forest Jul 01 2014
Actavis closes $28B Forest deal, names new CEO Jul 01 2014
Actavis closes $28B Forest deal, names new CEO Jul 01 2014
[video] Actavis completes deal to buy Forest Labs Jul 01 2014
Actavis Completes Forest Laboratories Acquisition Jul 01 2014
Actavis Completes Forest Laboratories Acquisition Jul 01 2014
Actavis and Forest Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Forest Jun 30 2014
U.S. allows Actavis Plc's purchase of Forest Labs with conditions Jun 30 2014
[$$] Actavis, Forest To Sell or Relinquish Generics Rights Jun 30 2014
Actavis and Forest Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Forest Jun 30 2014
[$$] Actavis Says Holders of 73% of Forest Shares Elect Stock Jun 30 2014
Actavis, Forest Labs announce merger consideration election results Jun 30 2014
Actavis and Forest Announce Preliminary Stockholder Merger Consideration Election Results Jun 30 2014
Actavis and Forest Announce Preliminary Stockholder Merger Consideration Election Results Jun 30 2014
Affiliated Managers Group Set to Join S&P 500; LaSalle Hotel Properties, Rayonier Advanced... Jun 24 2014
Forest Laboratories Reports Positive Data on Viibryd Jun 24 2014
After-hours buzz: Bristol-Myers Squibb, Walgreen & More Jun 24 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

Cjs804
ReplyCjs804 - 5 months ago
pfe

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK